Literature DB >> 15187097

Cutting Edge: NK cells mediate IgG1-dependent hyperacute rejection of xenografts.

Dengping Yin1, Huasong Zeng, Lianli Ma, Jikun Shen, Hui Xu, Guerard W Byrne, Anita S Chong.   

Abstract

Classic hyperacute rejection is dependent on the activation of the terminal components of complement. Recently, xenoantibodies with limited abilities to activate the classical pathway of complement in vitro have been implicated in the acute vascular rejection of xenografts. It is unclear how these Abs affect their pathogenic activities in vivo. In this study, we demonstrate the ability of an anti-Gal-alpha1,3Gal (Gal) IgG1, with modest complement-activating abilities in vitro, to induce xenograft rejection. This rejection was dependent on the activation of complement, on FcgammaR-mediated interactions, and on the presence of NK cells. Inhibition of any one of these factors resulted in the abrogation of IgG1-mediated rejection. In contrast, an anti-Gal IgG3 mAb induced classic, hyperacute rejection that was solely dependent on complement activation. Our observations implicate two types of IgG-mediated rejection; one that is dependent on complement activation, and a second that is uniquely dependent on complement, FcgammaR, and NK cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15187097     DOI: 10.4049/jimmunol.172.12.7235

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody.

Authors:  T Hirohashi; C M Chase; P Della Pelle; D Sebastian; A Alessandrini; J C Madsen; P S Russell; R B Colvin
Journal:  Am J Transplant       Date:  2011-11-09       Impact factor: 8.086

2.  In the absence of natural killer cell activation donor-specific antibody mediates chronic, but not acute, kidney allograft rejection.

Authors:  Takafumi Yagisawa; Toshiaki Tanaka; Satoshi Miyairi; Kazunari Tanabe; Nina Dvorina; Wayne M Yokoyama; Anna Valujskikh; William M Baldwin; Robert L Fairchild
Journal:  Kidney Int       Date:  2018-11-29       Impact factor: 10.612

Review 3.  An update on xenotransplantation.

Authors:  E Cozzi; M Seveso; S Hutabba; S Fabris; L Cavicchioli; E Ancona
Journal:  Vet Res Commun       Date:  2007-08       Impact factor: 2.459

4.  Neutralization of HIV-1 by redirection of natural antibodies.

Authors:  Maria F Perdomo; Michael Levi; Matti Sällberg; Anders Vahlne
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-21       Impact factor: 11.205

5.  Complement and Fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia.

Authors:  Jesse Wells; Constantine G Haidaris; Terry W Wright; Francis Gigliotti
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

6.  Impact of Mixed Xenogeneic Porcine Hematopoietic Chimerism on Human NK Cell Recognition in a Humanized Mouse Model.

Authors:  H W Li; P Vishwasrao; M A Hölzl; S Chen; G Choi; G Zhao; M Sykes
Journal:  Am J Transplant       Date:  2016-08-10       Impact factor: 8.086

Review 7.  Chronic alloantibody mediated rejection.

Authors:  R Neal Smith; Robert B Colvin
Journal:  Semin Immunol       Date:  2011-11-02       Impact factor: 11.130

8.  Complete absence of the αGal xenoantigen and isoglobotrihexosylceramide in α1,3galactosyltransferase knock-out pigs.

Authors:  Gisella L Puga Yung; Yunsen Li; Lubor Borsig; Anne-Laure Millard; Maria B Karpova; Dapeng Zhou; Jörg D Seebach
Journal:  Xenotransplantation       Date:  2012 May-Jun       Impact factor: 3.907

9.  Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice.

Authors:  T Hirohashi; S Uehara; C M Chase; P DellaPelle; J C Madsen; P S Russell; R B Colvin
Journal:  Am J Transplant       Date:  2010-01-05       Impact factor: 8.086

10.  mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.

Authors:  Christina L Avila; Jason M Zimmerer; Steven M Elzein; Thomas A Pham; Mahmoud Abdel-Rasoul; Ginny L Bumgardner
Journal:  Transplantation       Date:  2016-09       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.